Burning Rock Biotech Limited

Informe acción NasdaqGM:BNR

Capitalización de mercado: US$66.1m

Salud financiera de hoja de balance de Burning Rock Biotech

Salud financiera controles de criterios 6/6

Burning Rock Biotech tiene un patrimonio de los accionistas total de CN¥716.8M y una deuda total de CN¥0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CN¥984.9M y CN¥268.1M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

CN¥0

Deuda

Ratio de cobertura de interesesn/a
EfectivoCN¥572.62m
PatrimonioCN¥716.83m
Total pasivoCN¥268.09m
Activos totalesCN¥984.93m

Actualizaciones recientes sobre salud financiera

Recent updates

Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Jun 21
Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

Mar 25
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Feb 01
There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jul 12
Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Apr 28
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Dec 23
We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Sep 20
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Aug 31

Burning Rock Localizes As Investors Grow Impatient

Jun 06

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Nov 17

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

Aug 27
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Jul 23
A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

May 13
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

Burning Rock Biotech Expands Test Portfolio In Bid For Growth

Dec 30

Burning Rock inks license pact with Oncocyte Corporation

Dec 15

Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS

Dec 04

Burning Rock Biotech EPS misses by $0.08, beats on revenue

Nov 20

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥840.8M) de BNR superan a sus pasivos a corto plazo (CN¥255.4M).

Pasivo a largo plazo: Los activos a corto plazo de BNR (CN¥840.8M) superan a sus pasivos a largo plazo (CN¥12.7M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: BNR está libre de deudas.

Reducción de la deuda: BNR no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 82.8%.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BNR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: BNR dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 21.4% cada año.


Descubre empresas con salud financiera